Latest filing published 14 Mar 2025 for Repare Therapeutics Inc., €5,861. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michael Zinda, listed as senior executive, appears in our data through filings on Repare Therapeutics Inc. shares, published by SEC (Form 4). Over a trading history stretching from 17 May 2021 to 12 March 2025, the count stands at 13 filings.
Every open-market trade on record is a sale: 9 sales worth €915k. The rest of the record consists of 3 share grants and 1 option exercise. Since January 2025: no purchases and 1 sale on the market.
On 14 March 2025 came the latest disclosure, an open-market sale for €5,861 in Repare Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations